McMillan Shakespeare slumps on FBT fears

McMillan Shakespeare shares take a dive as FBT changes are targetted to make up the revenue shortfall from scrapping the carbon tax.

Carbon tax or emissions trading scheme?

Investors in McMillan Shakespeare clearly would prefer the former. For the accelerated move to a trading scheme and floating price appears to have come at a significant cost to the business.

Its shares were slammed this morning, dropping 14.7% to $15.36 before the company requested the stock exchange suspend trading in the stock.

The shares began to slide as Prime Minister Kevin Rudd and Treasurer Chris Bowen outlined the cost savings at a press conference in Townsville to compensate for the loss of revenue from the carbon tax.

The vast bulk of the $3.9 billion in savings will come from changes to the fringe benefits tax for vehicles used by companies and individuals, particularly around salary sacrificing. Those changes are expected to save $1.9 billion over the forward estimates.

Novated leasing for company cars and salary packaging forms the major part of McMillan Shakespeare’s business.

Of its five divisions, four relate to motor vehicle leasing and fleet management.

Interleasing is a fleet management specialist that runs FBT management, salary packaging and leasing of commercial and passenger vehicles.

Holden Leasing caters to commercial, small- to medium-sized enterprises and public sector leasing for General Motors vehicles.

While the division specialises in Holden, it also sources other vehicles. RemServe and Maxxia are also novated vehicle lease operations.

McMillan Shakespeare is part of the Uncapped 100.

InvestSMART FORUM: Come and meet the team

We're loading up the van and going on tour from April to June, with events on the NSW central & north coast, the QLD mid-north coast and in Perth, Adelaide, Melbourne, Sydney and Canberra. Come and meet the team and take home simple strategies that you can use to build an investment portfolio to weather any storm. Book your spot here.

Want access to our latest research and new buy ideas?

Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.

Sign up for free

Related Articles